BioVersys outlines antibacterial drug pipeline, flags BV100 Phase 3 as lead program

• BioVersys published a corporate presentation outlining its late-stage anti-infective pipeline, led by BV100 for carbapenem-resistant Acinetobacter baumannii hospital infections.
• BV100 Phase 3 RIV-TARGET reported first-patient-first-visit in April 2026; top-line data targeted for H1 2028.
• Alpibectir tuberculosis program advanced under GSK; Phase 2b/c pulmonary-TB trial reported first-patient-first-visit in March 2026.
• Cash and cash equivalents totaled CHF 69.3 million at June 30, 2026; funding runway guided into 2028.
• Peak sales guidance reiterated at about $800 million for BV100; alpibectir expected peak sales about $400 million, with 50% attributed to BioVersys.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.